mRNA治療市場：タイプ、用途、最終用途別-2025～2030年の世界予測

mRNA治療市場は、2023年に338億2,000万米ドルと評価され、2024年には419億9,000万米ドルに達すると予測され、CAGR 24.65％で成長し、2030年には1,582億米ドルになると予測されています。

mRNA治療とは、病気の治療や予防に役立つタンパク質の生産を細胞に指示するためのメッセンジャーRNAの使用を指します。この急速に発展しているセグメントは、COVID-19のような感染症からがんのような非感染症に至るまで、様々な健康状態に対処するために、ヒト細胞におけるタンパク質合成の自然なプロセスを活用しています。mRNA治療の必要性は、迅速な開発、拡大性、多用途性の可能性にあり、これらはすでにCOVID-19パンデミックへの効果的なワクチンによる迅速な対応で実証されています。主要用途と最終市場の範囲は、予防接種、がん免疫療法、希少遺伝性疾患などであり、個別化医療の有望な展望を提供しています。

mRNA治療の市場成長は、技術の進歩、官民からの資金提供の増加、バイオテクノロジー企業と製薬会社の戦略的提携によって大きく左右されます。最近のmRNAワクチンの成功は、関心と投資に拍車をかけ、感染症以外にもmRNAベースの治療を拡大する潜在的な機会をもたらしています。このような機会を生かすための提言としては、強固な研究開発インフラへの投資、戦略的提携の構築、市場参入を促進するための薬事規制への注力などが挙げられます。

市場開拓を阻む課題としては、開発コストの高さ、mRNA特有の不安定さによる保管や流通の複雑さ、長期的な安全性と有効性を証明するための規制上のハードルなどが挙げられます。さらに、製造能力の制約や知的財産権に関する紛争も大きな障壁となっています。

イノベーションと調査は、mRNAの安定性と送達システムの最適化、特定の細胞や組織を標的とする精度の向上、製造コストの削減を目標とすべきです。市場力学は、急速な技術革新、激しい競争、非常にダイナミックな規制要件によって特徴づけられます。アカデミアや研究機関とのコラボレーションは、この非常に有望なセグメントにおける貴重な洞察を提供し、先進的な戦略を推進することができます。

市場力学：急速に進化するmRNA治療市場の主要市場洞察を公開

mRNA治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患と感染症の罹患率の増加
  • がんワクチンと治療に対する需要の高まり
  • mRNA治療に対する需要の急増と、大規模シーケンシング・プロジェクトに対する政府のイニシアチブの急増
• 市場抑制要因
  • 高い調査コストとmRNA定量失敗の脅威
• 市場機会
  • バイオテクノロジー関連の研究開発（R&D）イニシアチブの活発化と医療技術の進歩
  • 新製品の強力なパイプラインによるがんの個別化治療の開発
• 市場課題
  • mRNA治療に関する規制上の懸念と戦略

ポーターのファイブフォース：mRNA治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、mRNA治療市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：mRNA治療市場における外部からの影響の把握

外部マクロ環境要因は、mRNA治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：mRNA治療市場における競合情勢の把握

mRNA治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：mRNA治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、mRNA治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：mRNA治療市場における成功への道筋を描く

mRNA治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患と感染症の発生率の増加
    • がんワクチンと治療の需要増加
    • mRNA治療の需要の高まりと大規模シーケンシングプロジェクトに対する政府の取り組みの増加
  • 抑制要因
    • 調査コストの高さとmRNAの定量化の失敗の脅威
  • 機会
    • バイオテクノロジー関連の重要な研究開発（R&D）イニシアチブと医療技術の進歩
    • 強力な新製品のパイプラインを備えたがんの個別化治療の開発
  • 課題
    • mRNA治療に関する規制上の懸念と戦略
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 mRNA治療市場：タイプ別

• イントロダクション
• 予防ワクチン
• 治療
• 治療ワクチン

第7章 mRNA治療市場：用途別

• イントロダクション
• 感染症
• 腫瘍学
• 稀な遺伝性疾患
• 呼吸器疾患

第8章 mRNA治療市場：最終用途別

• イントロダクション
• 病院・クリニック
• 研究機関

第9章 南北アメリカのmRNA治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のmRNA治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのmRNA治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abogen Biosciences
• Alnylam Pharmaceuticals, Inc.
• Arcturus Therapeutics
• AstraZeneca plc
• BioNTech SE
• CRISPR Therapeutics AG
• Deep Genomics
• Eli Lilly and Company
• GSK plc
• Laronde Inc.
• Moderna, Inc.
• Nutcracker Therapeutics, Inc.
• Sangamo Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Tracxn Technologies Limited
• Translate Bio, Inc. by Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. MRNA THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. MRNA THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MRNA THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 146. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The mRNA Therapeutics Market was valued at USD 33.82 billion in 2023, expected to reach USD 41.99 billion in 2024, and is projected to grow at a CAGR of 24.65%, to USD 158.20 billion by 2030.

mRNA therapeutics refers to the use of messenger RNA to instruct cells to produce proteins that can treat or prevent disease. This rapidly evolving field leverages the natural process of protein synthesis in human cells to address a variety of health conditions, ranging from infectious diseases, such as COVID-19, to non-communicable diseases like cancer. The necessity of mRNA therapeutics lies in its potential for rapid development, scalability, and versatility, which have already been demonstrated in the swift response to the COVID-19 pandemic with effective vaccines. The primary application and end-use scope encompass vaccinations, cancer immunotherapies, and rare genetic disorders, offering a promising outlook for personalized medicine.

Market growth in mRNA therapeutics is significantly influenced by technological advancements, increased funding from public and private sectors, and strategic collaborations between biotech firms and pharmaceutical companies. The recent success of mRNA vaccines has spurred interest and investment, leading to potential opportunities in expanding mRNA-based treatments beyond infectious diseases. Recommendations to capitalize on these opportunities include investing in robust R&D infrastructures, forging strategic alliances, and focusing on regulatory pathways to facilitate market entry.

Challenges curbing market growth involve the high cost of development, storage and distribution complexities due to mRNA's inherent instability, and regulatory hurdles in proving long-term safety and efficacy. Additionally, manufacturing capacity constraints and intellectual property disputes present significant barriers.

Innovation and research should target optimization of mRNA stability and delivery systems, improvement in the precision of targeting specific cells or tissues, and reducing production costs. The nature of the mRNA therapeutics market is characterized by rapid technological changes, strong competition, and highly dynamic regulatory requirements. Collaborations with academia and research institutions can provide valuable insights and drive forward-thinking strategies in this highly promising field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving mRNA Therapeutics Market

The mRNA Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of chronic and infectious diseases
  • Growing demand for cancer vaccines and treatments
  • Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
• Market Restraints
  • High cost of research and threat of failure in quantification of mRNA
• Market Opportunities
  • Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
  • Development of personalized therapeutics for cancer with strong pipeline of new products
• Market Challenges
  • Regulatory concerns and strategies for mRNA therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the mRNA Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the mRNA Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the mRNA Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the mRNA Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the mRNA Therapeutics Market

A detailed market share analysis in the mRNA Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the mRNA Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the mRNA Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the mRNA Therapeutics Market

A strategic analysis of the mRNA Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abogen Biosciences, Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics, AstraZeneca plc, BioNTech SE, CRISPR Therapeutics AG, Deep Genomics, Eli Lilly and Company, GSK plc, Laronde Inc., Moderna, Inc., Nutcracker Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Tracxn Technologies Limited, and Translate Bio, Inc. by Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the mRNA Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Prophylactic Vaccines, Therapeutic Drugs, and Therapeutic Vaccines.
• Based on Application, market is studied across Infectious Diseases, Oncology, Rare Genetic Diseases, and Respiratory Diseases.
• Based on End Use, market is studied across Hospitals & Clinics and Research Organizations.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of chronic and infectious diseases
    • 5.1.1.2. Growing demand for cancer vaccines and treatments
    • 5.1.1.3. Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of research and threat of failure in quantification of mRNA
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
    • 5.1.3.2. Development of personalized therapeutics for cancer with strong pipeline of new products
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory concerns and strategies for mRNA therapeutics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. mRNA Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Prophylactic Vaccines
• 6.3. Therapeutic Drugs
• 6.4. Therapeutic Vaccines

7. mRNA Therapeutics Market, by Application

• 7.1. Introduction
• 7.2. Infectious Diseases
• 7.3. Oncology
• 7.4. Rare Genetic Diseases
• 7.5. Respiratory Diseases

8. mRNA Therapeutics Market, by End Use

• 8.1. Introduction
• 8.2. Hospitals & Clinics
• 8.3. Research Organizations

9. Americas mRNA Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific mRNA Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa mRNA Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abogen Biosciences
• 2. Alnylam Pharmaceuticals, Inc.
• 3. Arcturus Therapeutics
• 4. AstraZeneca plc
• 5. BioNTech SE
• 6. CRISPR Therapeutics AG
• 7. Deep Genomics
• 8. Eli Lilly and Company
• 9. GSK plc
• 10. Laronde Inc.
• 11. Moderna, Inc.
• 12. Nutcracker Therapeutics, Inc.
• 13. Sangamo Therapeutics, Inc.
• 14. Sarepta Therapeutics, Inc.
• 15. Tracxn Technologies Limited
• 16. Translate Bio, Inc. by Sanofi S.A.